Earlier success in demonstrating the impact on CAD risk of PCSK9 LOF mutations that led to LDL lowering paved the way for an examination of the consequences of LOF mutations of the apoC-III gene, and control of apoC-III as a prime lipid-lowering target [35]. The gene discussed is APOC3; the disease is coronary artery disorder.